Dr. Vokes on PARP Inhibitors for NSCLC

Everett Vokes, MD
Published: Monday, Aug 28, 2017



Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses PARP inhibitors for patients with non-small cell lung cancer (NSCLC).

PARP inhibtors are currently being investigated in many different tumor types. Some PARP inhibitors are partially approved in breast and ovarian cancer, where they have been shown to be superior to some chemotherapy regimens, explains Vokes.

Since lung cancer has repair defects in DNA repair pathways, PARP inhibitors could possibly improve progression-free survival for patients with NSCLC.



Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses PARP inhibitors for patients with non-small cell lung cancer (NSCLC).

PARP inhibtors are currently being investigated in many different tumor types. Some PARP inhibitors are partially approved in breast and ovarian cancer, where they have been shown to be superior to some chemotherapy regimens, explains Vokes.

Since lung cancer has repair defects in DNA repair pathways, PARP inhibitors could possibly improve progression-free survival for patients with NSCLC.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging Liquid Biopsies in Tumor Characterization for NSCLC TherapyJan 31, 20181.5
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Publication Bottom Border
Border Publication
x